About Careers MedBlog Contact us

Two Drug Combination Improves Survival in Pancreatic Cancer patients

by Bidita Debnath on October 19, 2013 at 11:51 PM
Font : A-A+

 Two Drug Combination Improves Survival in Pancreatic Cancer patients

A study shows that the drug combination nab-paclitaxel and gemcitabine is more effective in the treatment of patients with advanced pancreatic cancer than gemcitabine alone, which has been the standard treatment for these patients up until now.

This is a multicentre phase III study, with centers participating from 11 countries in North America, Europe and Australia. The clinical trial, sponsored by Celgene Corporation, involved 861 patients, half of whom were administered the nab-paclitaxel/gemcitabine combination, while the other half received gemcitabine alone. Median overall survival was 8.5 months for nab-paclitaxel/gemcitabine versus 6.7 months for gemcitabine alone.


One-year survival rates were 35% and 22%, respectively, and two-year survival rates were 9% and 4%, respectively. Similar side effects were found in the new drug and gemcitabine alike. The trial report therefore concluded that the nab-paclitaxel/gemcitabine combination significantly improves overall survival and response rate in patients with advanced pancreatic cancer.

Dr Josep Tabernero, Head of the Medical Oncology Department at the Vall d'Hebron University Hospital, Director of the Vall d'Hebron Institute of Oncology (VHIO), and one of the co-authors of the study, confirmed that "the results of this study take a step in the right direction towards controlling advanced pancreatic cancer, a disease with a very poor prognosis. We are confident that the gemcitabine/nab-paclitaxel combination will become one of the reference treatments for this disease. New drugs in the pipeline in this field are already being gauged against this combination as the benchmark to beat. Along these lines, investigators at VHIO are developing promising laboratory model combinations for pancreatic cancer treatment."

New first-line treatment for pancreatic cancer

Pancreatic cancer is the fourth leading cause of cancer-related death in Europe and the United States. Gemcitabine therapy has been the standard first-line treatment in patients with unresectable, locally advanced or metastatic pancreatic cancer since 1997. In metastatic disease, one-year survival ranges from about 17 to 23%, while five-year survival is only 2%.

Although numerous phase II and III studies have been conducted on new drugs combined with gemcitabine, most have not shown significant improvement in survival among these patients. The nab-paclitaxel/gemcitabine combination opens a new treatment avenue in this patient population.

Source: Eurekalert


Recommended Reading

Latest Research News

 New Insights into How the Immune System Responds to Spinal-Cord Injuries
New study findings delineate how aging affects the immune response following Spinal cord injury (SCI) and highlight the participation of the spinal cord meninges in repair.
Nearsightedness: Atropine Eye Drops may Slow Progression in Kids
A recent clinical trial suggests that the first medication therapy to reduce the progression of nearsightedness in children could be on the way.
Autoimmune Diseases Affect One in Ten: Study
Autoimmune disorders were found to be linked to Sjogren's, systemic lupus erythematosus, and systemic sclerosis.
Remarkable Journey of Transforming Lives With Brain Pacemaker
Successful brain pacemaker implantation has helped a 51year old Parkinson's disease patient to revitalize her quality of life.
What Are the Effects of Healthy Lifestyle on Osteoarthritis?
Recent recommendations on lifestyle behaviors to prevent progression of rheumatic and musculoskeletal diseases revealed.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Two Drug Combination Improves Survival in Pancreatic Cancer patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests